1. Home
  2. Southern Africa
  3. South Africa

Anti-AIDS drug faces rejection

An antiretroviral drug used to block the transmission of HIV from mother to child could soon be banned by South Africa's Medicines Control Council (MCC) on grounds of safety. The HIV/AIDS drug nevirapine received approval for local use when activists won a court order forcing the government to provide it to HIV-positive mothers last year. However, despite a recent thumbs-up by the World Health Organisation (WHO), the MCC could deregister the drug after rejecting results of a key Ugandan study on nevirapine's efficacy. MCC director, Precious Matsoso, said the 1999 study had numerous flaws and registration would be revoked unless the German manufacturer, Boehringer-Ingelheim, provided additional safety and effectiveness data within 90 days. "We have to be cautious," Matsoso told Reuters. "If information is available that meets rigorous scientific standards, we will look at it."

This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

Share this article

Get the day’s top headlines in your inbox every morning

Starting at just $5 a month, you can become a member of The New Humanitarian and receive our premium newsletter, DAWNS Digest.

DAWNS Digest has been the trusted essential morning read for global aid and foreign policy professionals for more than 10 years.

Government, media, global governance organisations, NGOs, academics, and more subscribe to DAWNS to receive the day’s top global headlines of news and analysis in their inboxes every weekday morning.

It’s the perfect way to start your day.

Become a member of The New Humanitarian today and you’ll automatically be subscribed to DAWNS Digest – free of charge.

Become a member of The New Humanitarian

Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

Join